Patent expiries to hit glaucoma drug market growth until 2018

The global glaucoma therapeutics market was worth $3.0 billion in 2010, is forecast to show slow growth, with a compound annual growth rate (CAGR) of 0.6% between 2010 and 2018, a new analysis from GlobalData suggests.

The glaucoma therapeutics market is predicted to witness major revenue depletion over the next few years due to a string of patent expiries for major marketed products such as Pfizer’s Xalatan (latanoprost), Allergan’s Lumigan (0.01% and 0.03% bimatoprost) and Alphagan P (0.1% and 0.15% brimonidine tartrate ophthalmic solution). Pfizer’s Xalatan is the most prescribed drug for the treatment of glaucoma and it went off patent in 2010. The future market will witness domination by generic drugs, which will impact the valuations of the glaucoma therapeutics market.

To witness entry of me-too products and product extensions in the near future